SillaJen, Inc.

A215600

KR7215600008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 24/05/2024 am IST			5-day change	1st Jan Change
4,730 ^KRW	+0.64%		+1.61%	-21.56%

22/04	OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market	CI
27/03	SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC	CI

SillaJen, Inc.(KOSDAQ:A215600) dropped from S&P Global BMI Index

September 21, 2020 at 09:30 am IST

Latest news about SillaJen, Inc.

OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market	22/04	CI
SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC	27/03	CI
SillaJen to Raise 129.4 Billion Won via Shares Issuance	25/03	MT
SillaJen, Inc.(KOSDAQ:A215600) added to S&P Global BMI Index	18/23/18	CI
Switzerland's Basilea Pharmaceutica Secures $4 Million Milestone Payment for Oncology Asset	19/22/19	MT
SillaJen Resumes Trading on Kosdaq	13/22/13	MT
SillaJen Bags Licensing Right to Basilea Pharmaceutica's Oncology Drug	21/22/21	MT
Kosdaq Delists Biotechnology Company SillaJen	19/22/19	MT
An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. from SillaJen, Inc. for KRW 10.1 billion.	25/21/25	CI
SillaJen, Inc. announced that it has received KRW 40 billion in funding	31/21/31	CI
SillaJen, Inc. announced that it has received KRW 60 billion in funding from M2N Co.,Ltd	15/21/15	CI
SillaJen, Inc. announced that it expects to receive KRW 40 billion in funding	14/21/14	CI
SillaJen, Inc. announced that it expects to receive KRW 60 billion in funding from M2N Co.,Ltd	31/21/31	CI
M2N Co.,Ltd signed LOI to acquire SillaJen, Inc..	21/21/21	CI
SillaJen, Inc.(KOSDAQ:A215600) dropped from S&P Global BMI Index	21/20/21	CI
SillaJen, Inc.(KOSDAQ:A215600) dropped from FTSE All-World Index	21/20/21	CI
SillaJen, Inc. announced that it has received KRW 20 billion in funding	24/20/24	CI
SillaJen, Inc. announced that it expects to receive KRW 20 billion in funding	23/20/23	CI
Sillajen Announces Conclusions from Interim Futility Analysis of Phase 3 PHOCUS Trial in HCC	02/19/02	CI
SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)	06/19/06	CI
SillaJen, Inc. announced that it has received KRW 110 billion in funding	21/19/21	CI
SillaJen, Inc. announced that it expects to receive KRW 110 billion in funding	19/19/19	CI
SillaJen, Inc. Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Cemiplimab	20/18/20	CI
SillaJen, Inc.(KOSDAQ:A215600) added to FTSE All-World Index	19/18/19	CI
SillaJen, Inc.(KOSDAQ:A215600) added to FTSE All-World Index	19/18/19	CI

SillaJen Inc is a Korea-based company primarily engaged in the research and development of oncolytic virus immunotherapeutics. The Companyâs major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SILLAJEN, INC.	-21.56%	356M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B